Uwe Pelzer

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi Second-line therapy in refractory pancreatic cancer. results of a phase II study
    Uwe Pelzer
    Universitatsmedizin Berlin, CharitéCentrum fur Tumormedizin, Medizinische Klinik m S Hamatologie Onkologie, Berlin, Germany
    Onkologie 32:99-102. 2009
  2. ncbi Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study
    Uwe Pelzer
    Universitatsmedizin Berlin, Charité Centrum für Tumormedizin, CONKO Study Group, Augustenburger Platz 1, Berlin, Germany
    BMC Cancer 10:86. 2010
  3. ncbi First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group
    Uwe Pelzer
    Charité Centrum für Tumormedizin, Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    Cancer Chemother Pharmacol 68:1173-8. 2011
  4. ncbi Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group
    Uwe Pelzer
    Universitatsmedizin Berlin Charite, Centrum für Tumormedizin, Augustenburger Platz 1, 13353 Berlin, Germany
    Eur J Cancer 47:1676-81. 2011
  5. ncbi Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)
    Hanno Riess
    Charite Campus Virchow Clinic, Medical Clinic Hematology Oncology, Augustenburger Platz 1, 13353 Berlin, Germany
    BMC Cancer 8:361. 2008
  6. ncbi Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI
    Juri Ruf
    Klinik fur Strahlenheilkunde und PET Zentrum Berlin, Berlin, Germany
    Pancreatology 5:266-72. 2005

Collaborators

Detail Information

Publications6

  1. ncbi Second-line therapy in refractory pancreatic cancer. results of a phase II study
    Uwe Pelzer
    Universitatsmedizin Berlin, CharitéCentrum fur Tumormedizin, Medizinische Klinik m S Hamatologie Onkologie, Berlin, Germany
    Onkologie 32:99-102. 2009
    ....
  2. ncbi Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study
    Uwe Pelzer
    Universitatsmedizin Berlin, Charité Centrum für Tumormedizin, CONKO Study Group, Augustenburger Platz 1, Berlin, Germany
    BMC Cancer 10:86. 2010
    ..The positive influence of BIA determinate predictors by additional nutrition is currently under discussion...
  3. ncbi First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group
    Uwe Pelzer
    Charité Centrum für Tumormedizin, Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    Cancer Chemother Pharmacol 68:1173-8. 2011
    ..The study is based on our completed dose finding phase I trial...
  4. ncbi Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group
    Uwe Pelzer
    Universitatsmedizin Berlin Charite, Centrum für Tumormedizin, Augustenburger Platz 1, 13353 Berlin, Germany
    Eur J Cancer 47:1676-81. 2011
    ..We initiated a phase III multicentre study comparing OFF versus best supportive care (BSC) in patients with APC progressing while on gemcitabine therapy...
  5. ncbi Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)
    Hanno Riess
    Charite Campus Virchow Clinic, Medical Clinic Hematology Oncology, Augustenburger Platz 1, 13353 Berlin, Germany
    BMC Cancer 8:361. 2008
    ..This phase IIb study was designed to analyze the efficacy of enoxaparin in patients with locally advanced or metastatic pancreatic cancer undergoing systemic chemotherapy...
  6. ncbi Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI
    Juri Ruf
    Klinik fur Strahlenheilkunde und PET Zentrum Berlin, Berlin, Germany
    Pancreatology 5:266-72. 2005
    ..To determine the value of fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for the detection of recurrent pancreatic cancer in comparison to computed tomography (CT) and magnetic resonance imaging (MRI)...